» Articles » PMID: 26319493

Analysis of Radiation Therapy in a Model of Triple-negative Breast Cancer Brain Metastasis

Overview
Specialty Oncology
Date 2015 Aug 31
PMID 26319493
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Most cancer patients with brain metastases are treated with radiation therapy, yet this modality has not yet been meaningfully incorporated into preclinical experimental brain metastasis models. We applied two forms of whole brain radiation therapy (WBRT) to the brain-tropic 231-BR experimental brain metastasis model of triple-negative breast cancer. When compared to sham controls, WBRT as 3 Gy × 10 fractions (3 × 10) reduced the number of micrometastases and large metastases by 87.7 and 54.5 %, respectively (both p < 0.01); whereas a single radiation dose of 15 Gy × 1 (15 × 1) was less effective, reducing metastases by 58.4 % (p < 0.01) and 47.1 % (p = 0.41), respectively. Neuroinflammation in the adjacent brain parenchyma was due solely to a reaction from metastases, and not radiotherapy, while adult neurogenesis in brains was adversely affected following both radiation regimens. The nature of radiation resistance was investigated by ex vivo culture of tumor cells that survived initial WBRT ("Surviving" cultures). The Surviving cultures surprisingly demonstrated increased radiosensitivity ex vivo. In contrast, re-injection of Surviving cultures and re-treatment with a 3 × 10 WBRT regimen significantly reduced the number of large and micrometastases that developed in vivo, suggesting a role for the microenvironment. Micrometastases derived from tumor cells surviving initial 3 × 10 WBRT demonstrated a trend toward radioresistance upon repeat treatment (p = 0.09). The data confirm the potency of a fractionated 3 × 10 WBRT regimen and identify the brain microenvironment as a potential determinant of radiation efficacy. The data also nominate the Surviving cultures as a potential new translational model for radiotherapy.

Citing Articles

Radiotherapy in Preclinical Models of Brain Metastases: A Review and Recommendations for Future Studies.

Shi W, Tanzhu G, Chen L, Ning J, Wang H, Xiao G Int J Biol Sci. 2024; 20(2):765-783.

PMID: 38169621 PMC: 10758094. DOI: 10.7150/ijbs.91295.


Clonogenicity-based radioresistance determines the expression of immune suppressive immune checkpoint molecules after hypofractionated irradiation of MDA-MB-231 triple-negative breast cancer cells.

Gehre S, Meyer F, Sengedorj A, Grottker F, Reichardt C, Alomo J Front Oncol. 2023; 13:981239.

PMID: 37152024 PMC: 10157086. DOI: 10.3389/fonc.2023.981239.


Towards personalizing radiotherapy for brain metastasis.

Nat Med. 2022; 28(4):643-644.

PMID: 35411078 DOI: 10.1038/s41591-022-01776-5.


Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.

Monteiro C, Miarka L, Perea-Garcia M, Priego N, Garcia-Gomez P, Alvaro-Espinosa L Nat Med. 2022; 28(4):752-765.

PMID: 35411077 PMC: 9018424. DOI: 10.1038/s41591-022-01749-8.


Glial activation positron emission tomography imaging in radiation treatment of breast cancer brain metastases.

Badiuk S, Thiessen J, Maleki Vareki S, Foster P, Chen J, Wong E Phys Imaging Radiat Oncol. 2022; 21:115-122.

PMID: 35359488 PMC: 8961463. DOI: 10.1016/j.phro.2022.02.016.


References
1.
Cameron H, Glover L . Adult neurogenesis: beyond learning and memory. Annu Rev Psychol. 2014; 66:53-81. PMC: 5612417. DOI: 10.1146/annurev-psych-010814-015006. View

2.
Lorger M, Felding-Habermann B . Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol. 2010; 176(6):2958-71. PMC: 2877856. DOI: 10.2353/ajpath.2010.090838. View

3.
Camphausen K, Scott T, Sproull M, Tofilon P . Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res. 2004; 10(18 Pt 1):6066-71. DOI: 10.1158/1078-0432.CCR-04-0537. View

4.
Gondi V, Tome W, Mehta M . Why avoid the hippocampus? A comprehensive review. Radiother Oncol. 2010; 97(3):370-6. PMC: 2997490. DOI: 10.1016/j.radonc.2010.09.013. View

5.
Percy D, Ribot E, Chen Y, McFadden C, Simedrea C, Steeg P . In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol. 2011; 46(11):718-25. PMC: 7465076. DOI: 10.1097/RLI.0b013e318226c427. View